Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease

Respiration

Volumn 79, Issue 4, 2010, Pages 288-295

  Ulrich, Silvia ^a   Hersberger, Martin ^a   Fischler, Manuel ^a   Nussbaumer Ochsner, Yvonne ^a   Treder, Ursula ^a   Russi, Erich W ^a   Speich, Rudolf ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Genetic; Polymorphism; Pulmonary hypertension; Serotonin; Serotonin transporter

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HEART CATHETERIZATION; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

AGED; FEMALE; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 77949272806     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226243     Document Type: Article

References (40)

1. Barbera JA, Peinado VI, Santos S: Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003;21:892-905.
2. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M: 'Natural history' of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219-224.
3. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE: Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002;166:314-322.
4. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E: Longterm course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984;130:993-998.
5. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E: Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194.
6. Weitzenblum E, Chaouat A: Severe pulmonary hypertension in COPD: is it a distinct disease? Chest 2005;127:1480-1482.
7. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet AS, Dartevelle P, Housset B, Hamon M, Weitzenblum E, Adnot S: Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003;108:1839-1844.
8. Machado RD, Koehler R, Glissmeyer E, Veal C, Suntharalingam J, Kim M, Carlquist J, Town M, Elliott CG, Hoeper M, Fijalkowska A, Kurzyna M, Thomson JR, Gibbs SR, Wilkins MR, Seeger W, Morrell NW, Gruenig E, Trembath RC, Janssen B: Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;173:793-797.
9. Liolitsa D, Powell JF, Prince M, Lovestone S: Association study of the 5-HT(2A) receptor gene polymorphism, T102C and essential hypertension. J Hum Hypertens 2001;15:335-339.
10. Yamada S, Akita H, Kanazawa K, Ishida T, Hirata K, Ito K, Kawashima S, Yokoyama M: T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis 2000;150:143-148.
11. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
12. Droma Y, Hanaoka M, Ota M, Katsuyama Y, Koizumi T, Fujimoto K, Kobayashi T, Kubo K: Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation 2002;106:826-830.
13. Ahsan A, Mohd G, Norboo T, Baig MA, Pasha MA: Heterozygotes of NOS3 polymorphisms contribute to reduced nitrogen oxides in high-altitude pulmonary edema. Chest 2006;130:1511-1519.
14. Smith EM, Baillie JK, Thompson AA, Irving JB, Porteous D, Webb DJ: Endothelial nitric oxide synthase polymorphisms do not influence pulmonary artery systolic pressure at altitude. High Alt Med Biol 2006;7:221-227.
15. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995;152:S77-S121.
16. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(suppl 5):S1-S28.
17. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398-1420.
18. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H: Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531-1536.
19. Chaouat A, Naeije R, Weitzenblum E: Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-1385.
20. *5 allele by multiplex long PCR. Clin Chem 2000;46:1072-1077.
21. Muntwyler J, Marti-Jaun J, Luscher TF, Hanseler E, Hersberger M: The Asp298 but not the C-786 genotype of the endothelial nitric oxide synthase is reduced with age in healthy Swiss men. Clin Chem Lab Med 2005;43:971-973.
22. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE: A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996;2:41-45.
23. Ruegg C, Hersberger M, Wusk B, Rentsch K, Kullak-Ublick GA, von Eckardstein A, Maly FE: Detection of the Arg702Trp, Gly908Arg and Leu1007fsinsC polymorphisms of the NOD2/CARD15 gene by real-time PCR with melting curve analysis. Clin Chem Lab Med 2004;42:494-498.
24. McNeil K: Assessment of patients with pulmonary hypertension. Respiration 2008;76:373-374.
25. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J: Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002;29:2379-2381.
26. Morse JH: Genetic studies of pulmonary arterialhy per tension. Lupus 2003;12:209-212.
27. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S: Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000;105:1555-1562.
28. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S: Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 2002;121:97S-98S.
29. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-1150.
30. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
31. Koehler R, Olschewski H, Hoeper M, Janssen B, Grunig E: Serotonin transporter gene polymorphism in a cohort of German patients with idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hyper tension. Chest 2005;128:619S.
32. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, Eddahibi S: Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003;168:487-493.
33. Eddahibi S, Adnot S: Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res 2002;3:9.
34. Wang HL: The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension. Curr Opin Investig Drugs 2004;5:963-966.
35. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Ki noshita O: Seroton in receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003;60:692-699.
36. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M: Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981;36:752-758.
37. Ulrich S, Nicolls MR, Taraseviciene L, Speich R, Voelkel N: Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hyper tension. Respiration 2008;75:272-280.
38. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A: Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:493-498.
39. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP: Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998;113:576-583.
40. Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, Sitbon O, Simonneau G: Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:637-648.